Scholarlink

<p>Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor&#xa0;2 (HER2)-negative early breast cancer who meet the inclusion criteria of the monarchE or NATALEE trials and are thus at increased risk of recurrence benefit from intensified adjuvant endocrine therapy with abemaciclib (improved invasive disease-free survival [IDFS] and overall survival [OS]) for 2&#xa0;years combined with an aromatase inhibitor (AI) or tamoxifen ± gonadotropin-releasing hormone (GnRH) analogues, or ribociclib (improved IDFS) for 3&#xa0;years combined with AI ± GnRH analogues. Adequate side-effect management is essential with both agents, particularly during the first 3&#xa0;months, in order to maintain good quality of life, improve adherence to the planned multi-year treatment, and prevent unnecessary treatment discontinuation. In the metastatic setting, the therapeutic landscape has broadened considerably in recent years, and in hormone-dependent breast cancer, the use of the abovementioned agents enables oral treatment with good quality of life, with a&#xa0;switch to intravenous therapy generally only occurring in the third line.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue endokrine Therapiekonzepte beim Mammakarzinom

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月9日

查看全文
  • Daphne Gschwantler-Kaulich

摘要

Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who meet the inclusion criteria of the monarchE or NATALEE trials and are thus at increased risk of recurrence benefit from intensified adjuvant endocrine therapy with abemaciclib (improved invasive disease-free survival [IDFS] and overall survival [OS]) for 2 years combined with an aromatase inhibitor (AI) or tamoxifen ± gonadotropin-releasing hormone (GnRH) analogues, or ribociclib (improved IDFS) for 3 years combined with AI ± GnRH analogues. Adequate side-effect management is essential with both agents, particularly during the first 3 months, in order to maintain good quality of life, improve adherence to the planned multi-year treatment, and prevent unnecessary treatment discontinuation. In the metastatic setting, the therapeutic landscape has broadened considerably in recent years, and in hormone-dependent breast cancer, the use of the abovementioned agents enables oral treatment with good quality of life, with a switch to intravenous therapy generally only occurring in the third line.